Peptide nucleic acid as therapeutic agent


 PNA are synthetic analog of DNA with a repeating N-(2-aminoethyl)-glycine peptide backbone connected to purine and pyrimidine nucleobases via a linker. The unique properties of PNA, including resistance to enzymatic digestion, higher bio stability combined with great hybridization affinity toward DNA and RNA, it has attracted great attention toward PNA- based technology as a promising approach for gene alteration. However, an important challenge in utilizing PNA is poor intracellular uptake. Some strategies have been developed to enhance the delivery of PNA in order to reach cognate site.



 



 


    Related Conference of Peptide nucleic acid as therapeutic agent

    July 21-21, 2021

    1st Biosimilars

    London, UK
    July 23-23, 2021

    Biofuels and Bioenergy

    Dubai, UAE
    July 26-27, 2021

    5th International Conference on Bioscience and Biotechnology

    London, Aland Islands
    March 15-16, 2021

    12th Tissue Repair and Regeneration Congress

    Dubai, UAE
    July 30-30, 2021

    Glycobiology Biochem Conference 2021

    London, UK
    September 06-06, 2021

    27th Asia Pacific Biotechnology Congress

    London, UK
    September 13-14, 2021

    17th World Congress on Structural Biology

    Prague, Czech Republic
    September 27-28, 2021

    25th European Biotechnology Congress

    Dublin, Ireland
    November 08-09, 2021

    23rd Global Biotechnology Congress

    Singapore City, Singapore
    November 18-19, 2021

    25th World Congress on Pharmaceutical Biotechnology

    Barcelona, Spain
    December 01-02, 2021

    18th International Conference on Metabolomics and Proteomics

    Frankfurt, Germany
    December 03-04, 2021

    International Conference on Biotechnology

    Singapore, Singapore

    Peptide nucleic acid as therapeutic agent Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in